<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02556268</url>
  </required_header>
  <id_info>
    <org_study_id>17957</org_study_id>
    <nct_id>NCT02556268</nct_id>
  </id_info>
  <brief_title>Interaction With HIV Antiretroviral Agents</brief_title>
  <official_title>Potential Pharmacokinetic Interaction of Human Immunodeficiency Virus (HIV) Antiretroviral Agents as Fixed-dose Combinations and Riociguat in HIV Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the pharmacokinetic drug-drug interaction potential of fixed dose
      antiretroviral therapies, i.e. ATRIPLA, COMPLERA, STRIBILD, TRIUMEQ, or any approved
      antiretroviral protease inhibitor in combination with (preferably) TRIUMEQ, on the exposure
      to riociguat in HIV patients on a stable dose of one of these therapies.

      â€¢ To Assess the safety and tolerability of riociguat treatment in combination with these
      fixed-dose antiretroviral therapies.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 23, 2016</start_date>
  <completion_date type="Actual">December 7, 2016</completion_date>
  <primary_completion_date type="Actual">December 7, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC of riociguat</measure>
    <time_frame>at pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8 24 and 48 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of riociguat</measure>
    <time_frame>at pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8 24 and 48 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC of riociguat main metabolite M1 (BAY 60-4552)</measure>
    <time_frame>at pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8 24 and 48 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of riociguat main metabolite M1 (BAY 60-4552)</measure>
    <time_frame>at pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8 24 and 48 hours post-dose</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>HIV-DDI</condition>
  <arm_group>
    <arm_group_label>Riociguat and ATRIPLA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Riociguat and COMPLERA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Riociguat and STRIBILD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Riociguat and TRIUMEQ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Riociguat and antiretroviral protease inhibitor with TRIUMEQ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Riociguat (Adempas, BAY 63-2521)</intervention_name>
    <description>0.5 mg, Oral (fasted conditions), 1 single dose</description>
    <arm_group_label>Riociguat and ATRIPLA</arm_group_label>
    <arm_group_label>Riociguat and COMPLERA</arm_group_label>
    <arm_group_label>Riociguat and STRIBILD</arm_group_label>
    <arm_group_label>Riociguat and TRIUMEQ</arm_group_label>
    <arm_group_label>Riociguat and antiretroviral protease inhibitor with TRIUMEQ</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATRIPLA</intervention_name>
    <description>600 mg efavirenz, 200 mg emtricitabine, and 300 mg tenofovir disoproxil fumarate, i.e. 1 tablet, once daily</description>
    <arm_group_label>Riociguat and ATRIPLA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>COMPLERA</intervention_name>
    <description>200 mg emtricitabine, 25 mg rilpivirine, and 300 mg tenofovir disoproxil fumarate, i.e. 1 tablet, once daily</description>
    <arm_group_label>Riociguat and COMPLERA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>STRIBILD</intervention_name>
    <description>150 mg elvitegravir, 150 mg cobicistat, 200 mg emtricitabine, and 300 mg tenofovir disoproxil fumarate, i.e. 1 tablet, once daily</description>
    <arm_group_label>Riociguat and STRIBILD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TRIUMEQ</intervention_name>
    <description>600 mg abacavir, 50 mg dolutegravir, and 300 mg lamivudine, i.e. 1 tablet, once daily</description>
    <arm_group_label>Riociguat and TRIUMEQ</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antiretroviral protease inhibitor</intervention_name>
    <description>Any approved antiretroviral protease inhibitor such as atazanavir, darunavir, indinavir, ritonavir, and saquinavir ; consistent with the most recent prescribing information documents</description>
    <arm_group_label>Riociguat and antiretroviral protease inhibitor with TRIUMEQ</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients aged &gt;=18 to &lt;65 years with a confirmed diagnosis of HIV
             receiving a stable regimen of ATRIPLA, COMPLERA, STRIBILD, TRIUMEQ, or any approved
             antiretroviral protease inhibitor such as atazanavir, darunavir, indinavir, ritonavir,
             and saquinavir in combination with (preferably) TRIUMEQ consistent with the most
             recent prescribing information documents for at least 6 weeks before concomitant
             administration of a single oral dose of 0.5 mg riociguat

          -  No clinical evidence of pulmonary hypertension

          -  Written informed consent

        Exclusion Criteria:

          -  Severe diseases for which it can be assumed that the pharmacokinetics or effects of
             the study drug will not be normal

          -  History of coronary artery disease

          -  Symptomatic postural hypotension (e.g. dizziness, lightheadedness)

          -  History of bronchial asthma or any other airway disease

          -  Renal impairment with creatinine clearance &lt;15 mL/min

          -  Severe hepatic impairment (Child-Pugh class C)

          -  Systolic blood pressure below 100 mmHg
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://pharma.bayer.com/en/innovation-partnering/clinical-trials/trial-finder/</url>
    <description>Click here to find results for studies related to Bayer products.</description>
  </link>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2015</study_first_submitted>
  <study_first_submitted_qc>September 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2015</study_first_posted>
  <last_update_submitted>December 5, 2017</last_update_submitted>
  <last_update_submitted_qc>December 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Single-Dose, Open-Label, Non-Blinded, Non-Placebo-</keyword>
  <keyword>Controlled, Stratified Design</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
    <mesh_term>Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
    <mesh_term>Emtricitabine, Rilpivirine, Tenofovir Drug Combination</mesh_term>
    <mesh_term>Anti-Retroviral Agents</mesh_term>
    <mesh_term>Protease Inhibitors</mesh_term>
    <mesh_term>HIV Protease Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

